Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis  

作　　者：Matthew Peverelle Jonathan Ng James Peverelle Ryan D.Hirsch Adam Testro 

机构地区：[1]Liver transplant unit,Austin Health,Melbourne 3084,Australia [2]Liver transplant unit,Austin Health,Heidelberg 3084,Victoria,Australia

出　　处：《World Journal of Gastroenterology》2023年第47期6165-6167,共3页世界胃肠病学杂志（英文版）

摘　　要：There is rapidly increasing uptake of GLP-1 (glucagon-like peptide-1) agonistssuch as semaglutide worldwide for weight loss and management of non-alcoholicsteatohepatitis (NASH). remains a paucity of safety data in the vulnerable NASHcirrhotic population. We report herein the first documented case of liver decompensationand need for liver transplant waitlisting in a patient with NASHcirrhosistreated with semaglutide. Rapid weight loss led to the development ofascites and hepatic encephalopathy and an increase in the patients Model forEndstage Liver Disease-Na (MELD-Na) score from 11 to 22. Aggressive nutritionalsupplementation was commenced and the semaglutide was stopped. Overthe following months she regained her weight and her liver recompensated andher MELD-Na decreased to 13, allowing her to be delisted from the transplantwaitlist. This case serves as a cautionary tale to clinicians using semaglutide in thecirrhotic population and highlights the need for more safety data in this patientgroup.

关 键 词：Semaglutide Non-alcoholic steatohepatitis CIRRHOSIS Non-alcoholic steatohepatitis cirrhosis Glucagon-like peptide 1 agonists Weight loss 

分 类 号：R575.5[医药卫生—消化系统]